GENFIT Announces Two Oral Presentations at the Digital
International Liver Congress™ 2020
Lille, France; Cambridge, M.A.; August
26, 2020 - GENFIT (Nasdaq and Euronext:
GNFT), a late-stage biopharmaceutical company dedicated to
improving the lives of patients with metabolic and liver
diseases, announced two oral presentations on new
non-alcoholic steatohepatitis (NASH) data, at the Digital
International Liver Congress™ 2020, the 55th
Annual Meeting of the European Association for the Study of the
Liver (EASL), to be held virtually August 27-29, 2020.
The first presentation will highlight and
support the role of biomarker, miR-34a - a key component of NIS4™
technology - in ruling out NAFLD and its role in the identification
of patients with at-risk NASH.
The second presentation will discuss the
positive, pre-clinical data of GENFIT’s lead compound, elafibranor,
in combination with semaglutide, in reducing liver
inflammation.
The full scientific program for The Digital International Liver
Congress™ 2020 is available through the Digital International Liver
Congress website.
Oral
Presentations:
Title: Serum levels of miR-34a to rule-out
NAFLD in healthy subjects and identify NAFLD patients with active
NASH (NAS≥4) and significant liver fibrosis (F≥2)
Presentation Number: AS102
Presenter: Arun J. Sanyal
Authors: Stephen A. Harrison et al.
Session: August 27, 2020 – 12:15-12:30 CET –
Channel 3
Title: The combination of elafibranor and
semaglutide drastically improves fibrosing steatohepatitis and
distinctly modulates liver inflammatory signature
Presentation Number: AS014
Presenter: Robert Walczak
Authors: Vanessa Legry et al.
Session: August 28, 2020 – 15:45-16:00 CET –
Channel 3
ABOUT NIS4™
NIS4™ is GENFIT’s non-invasive, blood-based
diagnostic technology, which was developed to identify patients
with non-alcoholic steatohepatitis (NASH) and significant to
advanced fibrosis (F>2), also referred to as at-risk NASH. In
January 2019, GENFIT signed a licensing agreement with LabCorp® to
make NIS4™ technology available for use in clinical research
through their drug development subsidiary, Covance. GENFIT also
continues to explore opportunities to obtain formal marketing
authorization of an in vitro diagnostic (IVD) version of NIS4™ in
both the U.S. and European markets. For more information, please
visit: https://nis4.com.
ABOUT NASH
NASH is a liver disease characterized by an
accumulation of fat (lipid droplets), along with inflammation and
degeneration of hepatocytes. The disease is associated with an
increased risk of cardiovascular disease along with long-term risk
for progression to cirrhosis, leading to liver insufficiency and
potential progression to liver cancer. NASH is a serious disease
that often carries no symptoms in its early stages, but if left
untreated can result in cirrhosis, cancer, and the need for liver
transplant. The prevalence of NASH is rapidly increasing as a
result of the growing obesity and diabetes epidemics and is
believed to affect as much as 12 percent of people in the U.S. and
six percent worldwide.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to improving the lives of patients with metabolic and
liver diseases. GENFIT is a pioneer in the field of nuclear
receptor-based drug discovery, with a rich history and strong
scientific heritage spanning more than two decades. GENFIT plans to
initiate a Phase 3 clinical trial of elafibranor in patients with
PBC. As part of GENFIT’s comprehensive approach to clinical
management of patients with liver disease, the Company is also
developing NIS4™, a new, non-invasive blood-based diagnostic
technology which, if approved, could enable easier identification
of patients with at-risk NASH. With facilities in Lille and Paris,
France, and Cambridge, MA, USA, the Company has approximately 200
employees. GENFIT is a publicly traded company listed on the Nasdaq
Global Select Market and on compartment B of Euronext’s regulated
market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995, with respect
to GENFIT, including statements about the performance of NIS4™ in
the identification of NAFLD patients at risk of NASH and the
potential benefits of a combination of elafibranor and semaglutide
in the reduction of hepatic inflammation. The use
of certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the Company believes its
expectations are based on the current expectations and reasonable
assumptions of the Company’s management, these forward-looking
statements are subject to numerous known and unknown risks and
uncertainties, which could cause actual results to differ
materially from those expressed in, or implied or projected by, the
forward-looking statements. These risks and uncertainties include,
among other things, the uncertainties inherent in research and
development, including related to safety, biomarkers, progression
of, and results from, its ongoing and planned clinical trials,
review and approvals by regulatory authorities of its drug and
diagnostic candidates and the Company’s continued ability to raise
capital to fund its development, as well as those risks and
uncertainties discussed or identified in the Company’s public
filings with the French Autorité des marchés financiers (“AMF”),
including those listed in Section 2.1 “Main Risks and
Uncertainties” of the Company’s 2019 Universal Registration
Document filed with the AMF on May 27, 2020 under n° D.20-0503,
which is available on GENFIT’s website (www.genfit.com) and on the
website of the AMF (www.amf-france.org) and public filings and
reports filed with the U.S. Securities and Exchange Commission
(“SEC”), including the Company’s 20-F dated May 27, 2020. In
addition, even if the Company’s results, performance, financial
condition and liquidity, and the development of the industry in
which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments
in future periods. These forward-looking statements speak
only as of the date of publication of this document. Other than as
required by applicable law, the Company does not undertake any
obligation to update or revise any forward-looking information or
statements, whether as a result of new information, future events
or otherwise.
GENFIT CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press Relations | Tel: +3 33 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120
Loos - FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT Announces Two Oral Presentations at the Digital
International Liver Congress™ 2020